NPM1 and acute myeloid leukemia: Recently Lachowiez et al. reported very favorable responses to the venetoclax + HMAs combination in elderly patients with AML carrying NPM1 mutations, suggesting that this regimen could be an “optimal mutation-targeted treatment approach” in this subset, irrespective of BCL-2 intensity of expression [20].